Cancer Stem Cell & Oncology Research

Prostate Cancer Stem Cells

Nowadays, men over 50 are more likely to develop prostate cancer than ever before. Medical treatments for glandular carcinoma are backed by findings from the middle of the 20th century, although they are unlikely to be curative in the near future. The majority of treatments are focused on a target cell that expresses the androgen receptor and is highly proliferative, which constitutes the vast majority of cells in a prostate tumor. However, the observed resistance to the majority of medical therapy is frequently explained by the existence of a cancer vegetative cell that, like normal epithelial stem cells within the prostate, does not express androgen receptor and is relatively inactive. The phenotypic of glandular cancer stem cells resembles that of a basal cell, and cultures produced from malignancies, but not from benign tissues, exhibit a proliferation of RNAs linked with prostate cancer.